Clinical bottom line
Allergic reactions to COVID-19 protein-based therapeutic antibodies represent a clinically important but relatively uncommon challenge in allergy practice. Emerging evidence highlights the need for careful diagnosis and management protocols tailored to these agents, which differ mechanistically from vaccine-related reactions. Clinicians should maintain vigilance for immediate hypersensitivity manifestations, employ validated diagnostic approaches, and consider risk stratification to guide safe administration. Current data remain limited, warranting cautious interpretation and individualized patient care.
What the evidence shows
Protein-based therapeutic antibodies against COVID-19, including monoclonal antibodies targeting the SARS-CoV-2 spike protein, have become integral in managing high-risk patients with COVID-19 infection or exposure. These biologics differ from vaccines in composition and immunogenicity, influencing their allergic risk profiles (Du et al., 2022). Allergic reactions reported range from mild infusion-related symptoms to anaphylaxis, though incidence rates are not well established.
The pathophysiology of allergic reactions to these protein therapeutics likely involves IgE-mediated hypersensitivity or complement activation-related pseudoallergy (CARPA), similar to mechanisms described for lipid nanoparticle (LNP)-based COVID-19 vaccines (Moghimi et al., 2021). However, protein therapeutics may also elicit unique immune responses due to their molecular structure and excipients (Du et al., 2022).
Diagnosis relies on clinical history, symptom timing, and exclusion of alternative etiologies. Skin testing and in vitro assays have been proposed but lack standardized protocols for these agents (Maki et al., 2021). Management strategies emphasize prompt recognition and treatment of acute reactions, including epinephrine administration for anaphylaxis, and consideration of premedication or desensitization in select cases (Maki et al., 2021).
Pharmacovigilance data from recent surveillance reports indicate that allergic reactions to COVID-19 protein-based antibodies are infrequent but can be severe (Reactions Weekly, 2023). These reports underscore the importance of allergy specialist involvement in risk assessment and management planning.
Caveats and uncertainty
The evidence base for allergic reactions to COVID-19 protein-based therapeutic antibodies is evolving and limited by small case series, passive reporting, and lack of prospective studies. Incidence estimates vary, and risk factors remain poorly defined. Diagnostic testing methods are not validated specifically for these agents, raising concerns about sensitivity and specificity.
Comparisons with vaccine-related allergic reactions may not fully extrapolate due to differing immunogenic components and administration contexts. Furthermore, the influence of patient comorbidities, concomitant medications, and prior sensitizations on reaction risk is unclear.
Therapeutic antibody formulations and excipients vary, complicating generalizations. The role of desensitization protocols and premedication regimens requires further study to establish safety and efficacy.
How this may change practice
Clinicians should incorporate awareness of potential allergic reactions to COVID-19 protein-based therapeutic antibodies into their assessment of patients eligible for these treatments. A detailed allergy history and prior reaction documentation are essential. Referral to allergy specialists for evaluation and possible skin testing may be warranted in patients with suspected hypersensitivity.
Protocols for monitoring during and after administration should be established, with readiness to manage anaphylaxis. Premedication strategies may be considered on a case-by-case basis, especially in patients with prior reactions to biologics.
Ongoing pharmacovigilance and reporting of allergic events will enhance understanding and guide future recommendations. Clinicians should stay informed of emerging evidence and evolving guidelines to optimize patient safety.